📊 ANIP Key Takeaways
Is Ani Pharmaceuticals Inc. (ANIP) a Good Investment?
ANIP demonstrates strong operational efficiency with 12.6% operating margin and exceptional free cash flow generation ($171.4M, 19.4% FCF margin), indicating sustainable profitability despite the company's pharmaceutical sector challenges. However, the extraordinary 6965.8% revenue growth warrants investigation into acquisition activity or one-time gains rather than organic scaling, while elevated insider trading activity (42 Form 4 filings) suggests potential insider concerns about valuation or strategy.
ANI Pharmaceuticals shows strong fundamental momentum with very large revenue expansion, solid operating profitability, and robust free cash flow generation. The balance sheet appears healthy with good liquidity and manageable leverage, but the quality and sustainability of the extreme top-line growth need confirmation because earnings growth was much more modest than revenue growth.
Why Buy Ani Pharmaceuticals Inc. Stock? ANIP Key Strengths
- Robust free cash flow of $171.4M with 19.4% FCF margin demonstrates strong cash generation capability
- Healthy liquidity position with 2.71x current ratio and $285.6M cash on hand
- Solid operating margin of 12.6% and net margin of 8.9% indicate operational efficiency and profitability
- Conservative leverage with 0.54x debt-to-equity ratio and 3.4x interest coverage ratio
- Strong return on equity of 14.5% showing effective capital deployment
- Strong free cash flow generation with $171.39M of FCF and a 19.4% FCF margin
- Healthy liquidity profile with a 2.71x current ratio, 2.19x quick ratio, and $285.58M in cash
- Profitable operations with $111.09M operating income, 12.6% operating margin, and positive ROE/ROA
ANIP Stock Risks: Ani Pharmaceuticals Inc. Investment Risks
- Extraordinary revenue growth of 6965.8% is atypical and likely driven by acquisition/one-time event rather than organic growth—sustainability is highly questionable
- Unusually high insider Form 4 filings (42 in 90 days) may indicate insider concern about company direction or valuation
- Missing gross margin data prevents assessment of pricing power, manufacturing efficiency, and product mix quality
- Net income growth of only 1.5% YoY despite massive revenue growth suggests operational margin compression or unusual charges
- Long-term debt of $291.8M represents 54% of equity and may constrain financial flexibility for R&D or strategic investments
- Revenue growth of +6965.8% YoY may reflect acquisitions or base effects, raising questions about underlying organic growth quality
- Interest coverage of 3.4x is adequate but not especially strong for a pharmaceutical business with integration and execution risk
- Net income grew only 1.5% YoY despite massive revenue growth, suggesting possible margin pressure, acquisition costs, or earnings quality concerns
Key Metrics to Watch
- Organic revenue growth rate and contribution of acquisitions to current period revenue
- Gross margin trends and product-level profitability to assess pricing sustainability
- Insider transaction volume and direction—significant selling would raise additional concerns
- Free cash flow sustainability and capital allocation priorities (debt reduction vs. R&D investment)
- Operating margin trajectory as any integration costs or one-time benefits normalize
- Organic revenue growth and operating margin trend
- Interest coverage and debt reduction versus free cash flow
Ani Pharmaceuticals Inc. (ANIP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.71x current ratio provides a solid financial cushion.
ANIP Profit Margin, ROE & Profitability Analysis
ANIP vs Healthcare Sector: How Ani Pharmaceuticals Inc. Compares
How Ani Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ani Pharmaceuticals Inc. Stock Overvalued? ANIP Valuation Analysis 2026
Based on fundamental analysis, Ani Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ani Pharmaceuticals Inc. Balance Sheet: ANIP Debt, Cash & Liquidity
ANIP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ani Pharmaceuticals Inc.'s revenue has grown significantly by 309% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.85 reflects profitable operations.
ANIP Revenue Growth, EPS Growth & YoY Performance
ANIP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $148.3M | -$8.2M | $-0.49 |
| Q2 2025 | $138.0M | -$2.3M | $-0.14 |
| Q1 2025 | $137.4M | $15.7M | $0.69 |
| Q3 2024 | $131.8M | -$8.2M | $0.45 |
| Q2 2024 | $116.5M | -$2.3M | $-0.14 |
| Q1 2024 | $106.8M | $1.4M | $0.06 |
| Q3 2023 | $83.8M | -$8.6M | $0.45 |
| Q2 2023 | $73.9M | $6.2M | $0.29 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ani Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
ANIP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ani Pharmaceuticals Inc. (CIK: 0001023024)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ANIP
What is the AI rating for ANIP?
Ani Pharmaceuticals Inc. (ANIP) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ANIP's key strengths?
Claude: Robust free cash flow of $171.4M with 19.4% FCF margin demonstrates strong cash generation capability. Healthy liquidity position with 2.71x current ratio and $285.6M cash on hand. ChatGPT: Strong free cash flow generation with $171.39M of FCF and a 19.4% FCF margin. Healthy liquidity profile with a 2.71x current ratio, 2.19x quick ratio, and $285.58M in cash.
What are the risks of investing in ANIP?
Claude: Extraordinary revenue growth of 6965.8% is atypical and likely driven by acquisition/one-time event rather than organic growth—sustainability is highly questionable. Unusually high insider Form 4 filings (42 in 90 days) may indicate insider concern about company direction or valuation. ChatGPT: Revenue growth of +6965.8% YoY may reflect acquisitions or base effects, raising questions about underlying organic growth quality. Interest coverage of 3.4x is adequate but not especially strong for a pharmaceutical business with integration and execution risk.
What is ANIP's revenue and growth?
Ani Pharmaceuticals Inc. reported revenue of $883.4M.
Does ANIP pay dividends?
Ani Pharmaceuticals Inc. pays dividends, with $1.2M distributed to shareholders in the trailing twelve months.
Where can I find ANIP SEC filings?
Official SEC filings for Ani Pharmaceuticals Inc. (CIK: 0001023024) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ANIP's EPS?
Ani Pharmaceuticals Inc. has a diluted EPS of $3.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ANIP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ani Pharmaceuticals Inc. has a BUY rating with 74% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ANIP stock overvalued or undervalued?
Valuation metrics for ANIP: ROE of 14.5% (sector avg: 15%), net margin of 8.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ANIP stock in 2026?
Our dual AI analysis gives Ani Pharmaceuticals Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ANIP's free cash flow?
Ani Pharmaceuticals Inc.'s operating cash flow is $185.2M, with capital expenditures of $13.8M. FCF margin is 19.4%.
How does ANIP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 8.9% (avg: 12%), ROE 14.5% (avg: 15%), current ratio 2.71 (avg: 2).